Open-source software developer Seqera Labs raises $22m in Series A

By Jane Byrne

- Last updated on GMT

© GettyImages/Dilok Klaisataporn
© GettyImages/Dilok Klaisataporn

Related tags COVID-19 variant Astrazeneca Janssen

Addition, Talis Capital, and Speedinvest were among the investors participating in the round. Seqera Labs had previously secured €4.4m (US$4.3m) in seed funding, plus grants from the Chan Zuckerberg Initiative.

Seqera Labs, a provider of data orchestration and workflow software for life sciences, said the Series A follows a period of strong growth, with a 400% year-over-year revenue increase and a tripling of employees over the last 12 months. 

It outlined how its flagship data analysis platform has also managed to expand its footprint and achieve rapid adoption, being used by over 150 leading pharmaceutical and biotechnology companies, including AstraZeneca, Janssen Pharmaceuticals, and Oxford Nanopore. Its technology was used to discover and track Alpha, Delta, and Omicron variants of the COVID-19 virus.

New hires 

The latest funding will help it bolster its team, as well as to expand its product portfolio to be able to cover the entire data analysis lifecycle.

Founded in 2018 as a spin-off from the Centre for Genomic Regulation (CRG), following the initial success of Nextflow, Seqera looks to accelerate discovery and therapeutic breakthroughs through foundational open science software; it aims to empower scientists to assemble and deploy massively scalable data analysis pipelines in multi-cloud environments with minimal friction.

The plan going forward is to move beyond scientific workflows to encompass tool development, data management, reporting, infrastructure deployment, and interactive computing.

Jason Schneider of Addition said the biotechnology industry is undergoing a transformational shift and organizations must rapidly expand their capacity to process complex data at scale. “Seqera Labs’ products make this easier than ever before and allow research teams to remain focused on their critical work.”

Related topics Markets & Regulations

Related news

Show more

Follow us